We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
-11.87%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.29B
AUM Growth
-$271M
(-17%)
Cap. Flow
-$42.3M
Cap. Flow
% of AUM
-3.27%
Top 10 Holdings %
Top 10 Hldgs %
80.94%
Holding
37
New
–
Increased
7
Reduced
17
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SAGE
Sage Therapeutics
SAGE
|
+$2.63M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
+$2.1M |
| 3 |
Karyopharm Therapeutics
KPTI
|
+$1.26M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$935K |
| 5 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$703K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$7.58M |
| 2 |
United Therapeutics
UTHR
|
+$6.5M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$6.14M |
| 4 |
Align Technology
ALGN
|
+$5.4M |
| 5 |
Biogen
BIIB
|
+$5.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.39% |
| 2 | Financials | 1.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rigel Pharmaceuticals
RIGL
$782M
| $1.95M | 0.15% |
65,240
| – | – |
|
27
Mirum Pharmaceuticals
MIRM
$6.04B
| $1.43M | 0.11% |
64,700
| – | – |
|
28
Dianthus Therapeutics
DNTH
$6.29B
| $1.25M | 0.1% |
27,019
| – | – |
|
|
ALIM
29
DELISTED
Alimera Sciences
ALIM
| $1.13M | 0.09% |
200,919
| – | – |
|
30
Novavax
NVAX
$1.31B
| $921K | 0.07% |
12,500
| – | – |
|
31
Aldeyra Therapeutics
ALDX
$91.7M
| $715K | 0.06% |
160,800
| – | – |
|
32
Tactile Systems Technology
TCMD
$555M
| $546K | 0.04% |
27,100
| – | – |
|
|
KLDO
33
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $511K | 0.04% |
309,692
-31,338
| -9% | -$55.9K |
|
|
MRNS
34
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $293K | 0.02% |
31,330
| – | – |
|
35
UroGen Pharma
URGN
$2.39B
| $213K | 0.02% |
24,500
| – | – |
|
36
AstraZeneca
AZN
$246B
| – | – |
-14,630
| Closed | -$1.7M |
|
|
ZGNX
37
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-183,800
| Closed | -$2.99M |
|
Similar funds
AG
BL
PIM
ACA
PCM
HCM
ACM
DC
Palo Alto Investors's Q1 2022 Portfolio in Review
As of Q1 2022, Palo Alto Investors held 37 positions worth $1.29B, down 17% from $1.56B the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Palo Alto Investors withdrew a net $42.3M in Q1 2022, closing 2 positions and reducing 17 holdings. Its most notable exit was Zogenix, Inc., an estimated $2.99M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.
Against the trend, Palo Alto Investors added an estimated $2.63M to Sage Therapeutics.
- Palo Alto Investors added most to Sage Therapeutics in Q1 2022, an estimated $2.63M increase.
- Palo Alto Investors's biggest Q1 2022 reduction was Abiomed Inc, cutting an estimated $7.58M.
- Palo Alto Investors fully exited Zogenix, Inc. in Q1 2022, selling an estimated $2.99M.
- Palo Alto Investors's ten largest holdings make up 81% of its $1.29B portfolio in Q1 2022.
- Palo Alto Investors opened 0 new positions and closed 2 in Q1 2022.
- Palo Alto Investors's portfolio value fell 17% quarter-over-quarter to $1.29B.
Based on Palo Alto Investors's 13F filing for Q1 2022, filed 16 May 2022.